Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
4 hedge funds and large institutions have $451K invested in Loncar China BioPharma ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
5,005% more capital invested
Capital invested by funds: $8.83K → $451K (+$442K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$208K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GS
1
GTS Securities
New York
| $249K | +$267K | +15,393 | New |
|
|
2
Jane Street
New York
| $194K | +$208K | +11,978 | New |
|
|
BBPWM
3
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $4.98K | – | – | – |
|
4
Morgan Stanley
New York
| $3.04K | – | – | – |
|
CHNA Hedge Fund Activity: Q2 2023 in Review
4 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q2 2023, worth a combined $451K — up 5,005% from $8.83K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CHNA positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $208K.
- 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q2 2023, up from 3 in Q1 2023.
- Funds reported $451K of Loncar China BioPharma ETF stock for Q2 2023, up 5,005% quarter-over-quarter.
- 2 funds opened new Loncar China BioPharma ETF positions in Q2 2023 and 1 closed out, a net change of +1 holder.
- The largest Loncar China BioPharma ETF buyer in Q2 2023 was Jane Street, an estimated $208K added.
Based on aggregated 13F filings for Q2 2023.